2014
DOI: 10.4161/hv.27925
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of the immunogenicity of Cervarix®and Gardasil®human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
51
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 48 publications
(53 citation statements)
references
References 38 publications
(48 reference statements)
2
51
0
Order By: Relevance
“…the titres of 17-year-olds vaccinated at the age of 12 years are higher than those 17-year-olds vaccinated at the age of 15 years) [45][46][47][48]. (4) 2vHPV, due presumably to its adjuvant, induces greater antibody titres vs. HPV16 and HPV18 and invokes higher titres of cross-protective antibodies against untargeted HPV genotypes than 4vHPV [50][51][52][53][54]. (4) 2vHPV, due presumably to its adjuvant, induces greater antibody titres vs. HPV16 and HPV18 and invokes higher titres of cross-protective antibodies against untargeted HPV genotypes than 4vHPV [50][51][52][53][54].…”
Section: Humoral Immune Responsesmentioning
confidence: 99%
“…the titres of 17-year-olds vaccinated at the age of 12 years are higher than those 17-year-olds vaccinated at the age of 15 years) [45][46][47][48]. (4) 2vHPV, due presumably to its adjuvant, induces greater antibody titres vs. HPV16 and HPV18 and invokes higher titres of cross-protective antibodies against untargeted HPV genotypes than 4vHPV [50][51][52][53][54]. (4) 2vHPV, due presumably to its adjuvant, induces greater antibody titres vs. HPV16 and HPV18 and invokes higher titres of cross-protective antibodies against untargeted HPV genotypes than 4vHPV [50][51][52][53][54].…”
Section: Humoral Immune Responsesmentioning
confidence: 99%
“…HPV vaccinations have proven safe and immunogenic in immunosuppressed patients, inducing seroconversion in 95–100% of HIV-positive patients, but antibody titers were lower compared to healthy controls, which might be improved by additional vaccine boosts [2123]. Importantly, a prevalent infection with one vaccine-targeted HPV type did not negatively influence antibody induction against other vaccine types, and no effect was seen on CD4+ cell counts or HIV RNA levels.…”
Section: Introductionmentioning
confidence: 99%
“…In the 12-month follow-up period it was observed that HIV-infected women but not men reacted more strongly against Cervarix compared with Gardasil. Both vaccines induced comparable titers of neutralizing antibodies against nonvaccine HPV-31, -33 and -45 [60]. It would be interesting to determine long-term persistence of antibody titers in these study populations.…”
Section: Hpv Vaccination Of Hiv-positive and Immunosuppressed Individualsmentioning
confidence: 96%